EUCTR2005-005010-20-NO进行中（未招募）1 期
A double-blind, randomized, multicenter study to evaluate the effectiveness of the combination of valsartan and amlodipine in hypertensive patients not controlled on monotherapy
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female patients =18 years of age
- •2.Non-diabetic patients must have MSSBP of =140 mmHg and/or MSDBP =90 mmHg at Visits 1 and 2. Diabetic patients must have MSSBP =130 mmHg and/or MSDBP =80 mmHg at Visits 1 and 2
- •3.Patients treated with monotherapy at a dose considered as adequate by the investigator for a minimum of two months prior to Visit 1
- •4.Written informed consent to participate in the study prior to any study procedures
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Known or suspected contraindications, including history of allergy to ARBs, CCB, thiazides or to drugs with similar chemical structure
- •2.MSSBP =180 mmHg and/or MSDBP =110 mmHg (MSSBP =160 mmHg and/or MSDBP =100 mmHg for diabetic patients) at any time between Visit 1 and Visit 2.
- •3.Evidence of a secondary form of hypertension, to include coarctation of the aorta, primary hyperaldosteronism, renal artery stenosis, or pheochromocytoma
- •4.Known Keith-Wagener grade III or IV hypertensive retinopathy
- •5.History of hypertensive encephalopathy, cerebrovascular accident or myocardial infarction
- •6.History of transient ischemic attack 12 months prior to Visit 1
- •7.Percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG) 12 months prior to Visit 1
- •8.Diabetes mellitus type 1
- •9.Poorly controlled type 2 diabetes mellitus, i.e. glycosylated hemoglobin (HbA1c) >8.0%
- •10.History of heart failure Grade II - IV according to the NYHA classification
- •11.Second or third degree heart block without a pacemaker
- •12.Concomitant unstable angina pectoris
- •13.Concomitant potentially life threatening arrhythmia or symptomatic arrhythmia
- •14.Clinically significant valvular heart disease
- •15.Evidence of hepatic disease as determined by one of the following: ALT or AST values >3 x UNL at visit 1, a history of hepatic encephalopathy, a history of esophageal varices, or a history of portocaval shunt
- •16.Evidence of renal impairment as determined by one of the followings: serum creatinine >1.5 x UNL at visit 1, a history of dialysis, or a history of nephrotic syndrome
- •17.Serum sodium value < 135 mmol/L at visit 1
- •18.Serum potassium values <3.5 mmol/L or >5.5 mmol/L at visit 1
- •19.Any surgical or medical condition which might alter the absorption, distribution, metabolism, or excretion of any drug
- •20.Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 weeks post surgical bilateral oophorectomy and/or hysterectomy OR are using one or more of the following acceptable methods of contraception: surgical sterilization (e.g., bilateral tubal ligation, hysterectomy), hormonal contraception (implantable, patch, oral), and double –barrier methods1 (any double combination of: IUD, male or female condom with spermicidal gel, diaphragm, sponge, cervical cap)
- •21.Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mIU/ml)
- •22.Any surgical or medical condition which, at the discretion of the investigator, place the patient at higher risk from his/her participation in the study, or are likely to prevent the patient from complying with the requirements of the study or completing the trial period
- •23.History of malignancy of any organ system within the past five years, treated or untreated, including leukemia and lymphoma (but not basal cell skin cancer) whether or not there is evidence of local recurrence of metastases
- •24.Any severe, life-threatening disease within the past five years
- •25.History of drug or alcohol abuse within the last 2 years
研究者
相似试验
进行中（未招募）
1 期
A double-blind, randomized, multicenter study to evaluate the effectiveness of the combination of valsartan and amlodipine in hypertensive patients not controlled on monotherapyMedDRA version: 7.1Classification code 10020772HYpertensionEUCTR2005-005010-20-SKovartis Pharma Services AG926
进行中（未招募）
1 期
A double-blind, randomized, multicenter study to evaluate the effectiveness of the combination of valsartan and amlodipine in hypertensive patients not controlled on monotherapyHYpertensionEUCTR2005-005010-20-BEovartis Pharma Services AG
进行中（未招募）
不适用
A double-blind, randomized, multicenter study to evaluate the effectiveness of the combination of valsartan and amlodipine in hypertensive patients not controlled on monotherapyHYpertensionEUCTR2005-005010-20-ESovartis Farmacéutica, S.A.926
进行中（未招募）
1 期
Efficacy and safety of ALX-0171 in adults hematopoietic stem cell transplant (HST) recipients who present with an respiratory syncytial virus (RSV) infectioRespiratory Syncytial Virus InfectionEUCTR2017-003356-23-ITABLYNX NV75
进行中（未招募）
1 期
Efficacy and safety of ALX-0171 in adults hematopoietic stem cell transplant (HST) recipients who present with an respiratory syncytial virus (RSV) infectioMedDRA version: 20.1Level: PTClassification code 10061603Term: Respiratory syncytial virus infectionSystem Organ Class: 10021881 - Infections and infestationsRespiratory Syncytial Virus InfectionEUCTR2017-003356-23-BEAblynx NV75